ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "corticosteroids"

  • Abstract Number: 1007 • 2013 ACR/ARHP Annual Meeting

    Dose Of Corticosteroid, Risk Of Adverse Events and Healthcare Resource Utilization In Systemic Lupus Erythematosus

    Wei-Shi Yeh1, Shih-Yin Chen2, Kathleen McCarty3, Qian Li2, Yuan-Chi Lee2 and Nathalie Franchimont3, 1Biogen Idec, Cambridge, MA, 2United BioSource Corporation, Lexington, MA, 3Biogen Idec Inc., Weston, MA

    Background/Purpose: Gluco-corticosteroids (GCs) are frequently used to treat autoimmune disease and their chronic use has long been known to cause adverse events (AEs). The purpose…
  • Abstract Number: 1656 • 2012 ACR/ARHP Annual Meeting

    Treatment of Systemic Necrotizing Vasculitides in Patients ≥65 Years Old: Results of the Multicenter Randomized Cortage Trial

    Christian Pagnoux1, Thomas Quemeneur2, Jacques Ninet3, Elodie Perrodeau4, Elizabeth Diot5, Xavier Kyndt6, Benoit de Wazières7, jean-Luc Reny8, Xavier Puéchal9, Pierre-Yves Leberruyer10, Olivier Lidove11, Philippe Vanhille12, Pascal Godmer13, Aimé Albath-Sadiki14, Boris Bienvenu15, Pascal Cohen16, Luc Mouthon17, Philippe Ravaud4, Loic Guillevin18 and French Vasculitis Study Group (FVSG)19, 1Internal Medicine, Department of Internal Medicine, National Referral Center for Necrotizing Vasculitides and Systemic Sclerosis, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Université Paris – Descartes, Paris, France, Paris, France, 2Internal medicine, CHR de Valenciennes, Valenciennes, France, 3Department of Nephrology and Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, 4Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 5Department of Internal Medicine, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France, Tours, France, 6Department of Nephrology and Internal Medicine, CH, Valenciennes, Valenciennes, France, 7Department of Internal Medicine and Gerontology, Hôpital Universitaire Carémeau, Nîmes, France, Nimes, France, 8Service de médecine interne générale Hôpitaux universitaires de Genève, Geneve, Switzerland, 9National Referral Center for Rare Systemic Auto-immune Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, 10Hôpital Robert Debré, Centre Hospitalier Universitaire de Reims, Reims, France, Reims, France, 11Médecine interne, Hôpital Croix-Saint-Simon, PARIS, France, 12Department of Nephrology and Internal Medicine, Hospital of Valenciennes, Valenciennes, France, Valenciennes, France, 13Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, 14Urc, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, 27 rue du faubourg Saint Jacques, Paris, 75014, France, Paris, France, 15Médecine interne, CHU Côte de Nacre, CAEN, France, 16National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, 17Internal Medicine, Hopital Cochin, Paris, France, 18Internal Medicine, Cochin University Hospital, Paris, France, 19Department of Internal Medicine, National Referral Center for Necrotizing Vasculitides and Systemic Sclerosis, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Université Paris – Descartes, Paris, France

    Background/Purpose: To optimize the therapeutic strategy for the elderly with systemic necrotizing vasculitides (SNV; polyarteritis nodosa (PAN), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) or…
  • Abstract Number: 1139 • 2012 ACR/ARHP Annual Meeting

    Inhaled Nitrous Oxide Facilitates Access to Intra-Articular Corticosteroid Injections in Children with Juvenile Idiopathic Arthritis

    Mercedes O. Chan1, Ruth Wyllie2 and H. E. Foster3, 1Department of Pediatrics, Division of Pediatric Rheumatology, University of British Columbia and British Columbia's Children's Hospital, Vancouver, BC, Canada, 2Paediatric Rheumatology, Newcastle Hospitals, NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom, 3Paediatric Rheumatology, Newcastle Hospitals NHS Foundation Trust, Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood affecting 1 in 1000 children. Medical management for arthritis often includes intra-articular…
  • Abstract Number: 184 • 2012 ACR/ARHP Annual Meeting

    The Retrospective Review of 39 Intestinal Behcet’s Disease Focusing On the Requirement for the Immunosuppresive Drugs Other Than Corticosteroid

    Yoshitaka Kimura1, Kurumi Asako2, Hirotoshi Kikuchi2, Akiteru Takeuchi3 and Hajime Kono2, 1Department of Internal Medicine, Teikyo University school of medecine, Tokyo, Japan, 2Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 36-7-8 Arakawa, Tokyo, Japan

    Background/Purpose: To examine the demography, clinical characteristics, features of intestinal lesions, treatment, and prognosis in patients with the intestinal Behcet’s disease currently followed at a…
  • Abstract Number: 98 • 2012 ACR/ARHP Annual Meeting

    How to Assess Risks for Pulmonary Infection in Patients Receiving Immunosuppressive Treatment for Rheumatic Diseases? A Report From a Large-Scale Prospective Cohort Study

    Hayato Yamazaki1, Ryoko Sakai1, Ryuji Koike2, Yasunari Miyazaki3, Michi Tanaka1, Toshihiro Nanki1, Kaori Watanabe1, Shinsuke Yasuda4, Takashi Kurita5, Yuko Kaneko6, Yoshiya Tanaka7, Yasuhiko Nishioka8, Yoshinari Takasaki9, Kenji Nagasaka10, Koichi Amano11, Shigeto Tohma12, Makoto Dohi13, Takahiko Sugihara14, Haruhito Sugiyama15, Yasushi Kawaguchi16, Naohiko Inase17, Sae Ochi18, Hiroyuki Hagiyama19, Nobuyuki Miyasaka20 and Masayoshi Harigai21, 1Department of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, 2Clinical Research Center, Tokyo Medical and Dental University, Tokyo, Japan, 3Department of Integrated Pulmonology, Tokyo Medical and Dental University, Tokyo, Japan, 4Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, 5Department of Medicine II, Hokkaido University, Sapporo, Japan, 6Dept of Internal Medicine, Keio Univ School of Medicine, Tokyo, Japan, 7The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 8Department of Respiratory Medicine & Rheumotology, The Univeristy of Tokushima Graduate School, Tokushima, Japan, 9Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 10Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, 11Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, 12Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan, 13Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 14Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, 15Division of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan, 16Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 17Dept of Integrated Pulmonology, Tokyo Medical and Dental University, Tokyo, Japan, 18Department of Rheumatology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan, 19Department of Rheumatology, Yokohama-city Bay Red Cross Hospital, Yokohama, Japan, 20Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, 21Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan

    Background/Purpose: Patients with rheumatic diseases given immunosuppressive therapy are susceptible to various types of infections, especially pulmonary infections that affect their vital prognosis. The aim…
  • Abstract Number: 2655 • 2012 ACR/ARHP Annual Meeting

    Rapid and Effective Response to Immunosuppression in Treating Macrophage Activation Syndrome Associated with a Heterozygous Dominant Negative Mutation in RAB27a Leading to Decreased Cytolytic Activity

    Randy Q. Cron1, Mingce Zhang2, Christina J. Bemrich-Stolz2 and Timothy Beukelman1, 1Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Pediatrics, Univ of Alabama-Birmingham, Birmingham, AL

    Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is an often fatal disorder of infancy resulting from homozygous mutations in proteins involved in cytolysis (e.g. MUNC13-4, RAB27a, Perforin 1,…
  • Abstract Number: 2349 • 2012 ACR/ARHP Annual Meeting

    Corticosterois Therapy Restaured Treg/Th17 Balance in Patients with Polimyalgia Rheumatica

    Lorena Alvarez-Rodriguez1, Marcos Lopez-Hoyos2, Jaime Calvo-Alen3, Elena Aurrecoechea4, Teresa Ruiz Jimeno4, Ignacio Villa4, Carmen Gonzalez-Vela5 and Victor M. Martinez-Taboada1, 1Rheumatology, Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain, 2Immunology, Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain, 3Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, 4Rheumatology, Hospital de Sierrallana, Torrelavega, Spain, 5Pathology Anatomy, Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain

    Background/Purpose: To characterize the levels of circulating T regulatory cells (Tregs) and Th17 cells in polymyalgia rheumatica (PMR). Methods: The study included 46 patients with…
  • Abstract Number: 2241 • 2012 ACR/ARHP Annual Meeting

    Efficacy of Belimumab in Systemic Lupus Erythematosus Patients with High Baseline Disease Activity

    Ann E. Clarke1, Susan Manzi2, Michelle Petri3, Richard Furie4, Ronald F. van Vollenhoven5, Simon Cooper6, Z. John Zhong6, William W. Freimuth6 and Arthur Weinstein7, 1Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, 2Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4North Shore-LIJ Health System, Lake Success, NY, 5Karolinska University Hospital, Stockholm, Sweden, 6Human Genome Sciences, Inc., Rockville, MD, 7Washington Hospital Center, Washington, DC

    Background/Purpose: To assess the efficacy of belimumab in patients with SLE who had high disease activity at baseline, as defined by SELENA-SLEDAI score ≥10.  Methods: In…
  • Abstract Number: 1647 • 2012 ACR/ARHP Annual Meeting

    Critical Management Decisions in Cardiac Neonatal Lupus: The Role of Fluorinated Steroids

    Peter M. Izmirly1, Sara Sahl1, Amit Saxena2, Nathalie Costedoat-Chalumeau3, Jean-Charles Piette4, Munther A. Khamashta5, Cecilia Pisoni6, Deborah Friedman7 and Jill P. Buyon1, 1Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 2Rheumatology, New York University School of Medicine, New York, NY, 3Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 4Department of Internal Medicine 1., CHU Pitié-Salpêtrière, Paris, France, 5Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, 6Section of Rheumatology and Immunology, Centro de Educación, CEMIC, CABA, Argentina, 7Division of Pediatric Cardiology, New York Medical College, Valhalla, NY

    Background/Purpose: Life-threatening cardiac manifestations of neonatal lupus (cardiac-NL) include complete block, endocardial fibroelastosis (EFE) and dilated cardiomyopathy (DCM), all supportive of intense fibrosis at the…
  • Abstract Number: 1651 • 2012 ACR/ARHP Annual Meeting

    Higher Corticosteroid Doses Early in Disease Have A Long-Term Influence On Metabolic Syndrome in Systemic Lupus Erythematosus: Data from an International Inception Cohort

    Ben Parker1, Murray B. Urowitz2, Dafna D. Gladman3, Mark Lunt4, Ian N. Bruce5 and Systemic Lupus International Collaborating Clinic (SLICC)6, 1Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 2Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 5Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom, 6Toronto

    Background/Purpose: The Metabolic Syndrome (MetS) is a clustering of metabolic abnormalities associated with an increased risk of developing diabetes and atherosclerosis, and may add to…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology